RecruitingPhase 3NCT05879276

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.

Studying Cardiogenic shock

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Central Hospital, Nancy, France
Principal Investigator
Nicolas GIRERD, MD PhD
CHRU of NANCY
Intervention
Empagliflozin 10 MG(drug)
Enrollment
164 enrolled
Eligibility
18 years · All sexes
Timeline
2024 – 2027

Study locations (8)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05879276 on ClinicalTrials.gov

Other trials for Cardiogenic shock

Additional recruiting or active studies for the same condition.

See all trials for Cardiogenic shock →

← Back to all trials